Bone Biologics Corporation (BBLG) Actualités

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation (“Bone Biologics” or the “Company”...

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form EFFECT - Notice of Effectiveness

Form 424B4 - Prospectus [Rule 424(b)(4)]

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form 8-K - Current report